Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

• Status: Unknown status
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Young-Hak Kim, MD, PhD

Criteria

Inclusion Criteria:

• Age between 20 and 80 years

• Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks

• Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy

• mild gastrointestinal symptom

• Creatinen in blood ≤ 3mg/dl

• BUN ≤ 50mg/dl

• Birilubin ≤ 3mg/dl

• AST and ALT ≤ 80U/L

Exclusion Criteria:

• Pregnant or breast feeding

• History of Stomach or esophagus surgery

• Peptic ulcer or reflux esophagitis

• Zollinger-Ellison syndrome or primary esophageal motility disorders

• Malignant tumor

• Bleeding tendency or coagulopathy

• Contraindication of ALBIS

• Long term use of aspirin or P2Y12 receptor antagonist within 1month

• Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed)

• Terminal patient